Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Surface oncology

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Research Partnership

- PMLiVE

Woodford investment pushes Dementia Discovery Fund to £100m

Fund aims to back 40 projects over its 15-year term

- PMLiVE

Walmsley steps up to chief executive role at GSK

The firm's first female CEO, she takes over from Sir Andrew Witty

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

Blue Latitude Health

- PMLiVE

Caring for prostate cancer patients

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’...

Blue Latitude Health

- PMLiVE

Riding the wave of digital disruption

The challenges and rewards of meeting consumer expectations

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

- PMLiVE

Argos hit as kidney cancer immunotherapy fails phase III trial

Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

- PMLiVE

New guide to improve cancer control published in EU

Outlines recommendations to boost quality of life and reduce financial burden

- PMLiVE

Winning the war against cancer

Dr Josep Figueras on survival, access to treatments and the need for good data in oncology

- PMLiVE

Seattle Genetics signs $2bn deal for Immunomedics’ cancer drug

Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links